Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 5.9 billion in assets and investment in over 380 companies.
She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), Venus MedTech (HKSE:2500), CanSino Biologics (SSE:688185; HKSE:6185), New Horizon Health (HKSE:6606), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, Valgen, Insilico Medicine among others. Her other investments include Gan & Lee (SSE:603087), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus, CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MEDx, Cure Genetics, SinoCell Tech (SSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) , Jacobio (HKSE:1167), Zhenge, Hope Medicine among others.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020 and 2021, named Best Women VCs List by Forbes China (#2 in 2021, #3 in 2018) and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.